A 57% complete response rate in stage III unresectable NSCLC stops you cold — the current standard of care, concurrent chemoradiation plus durvalumab, delivers complete responses in fewer than 5% of patients. That is the number anchoring the CONVERGE Part 1 readout presented at ESTRO 2026, and it reframes what radiotherapy augmentation with a nanoparticle agent might actually accomplish in a disease where depth of response has long been the ceiling nobody could raise.
The dataset is small — seven evaluable patients who completed the full regimen of JNJ-1900 (NBTXR3) with concurrent chemoradiotherapy and durvalumab consolidation. Seven patients is not a trial result; it is a signal that demands interrogation. But the internal coherence is striking: 100% disease control, 86% overall response, and four complete responses in a population where complete responses are essentially a rounding error under standard treatment. NBTXR3’s mechanism matters here. The hafnium oxide nanoparticles are injected once intratumorally, activated by the radiotherapy that would be delivered regardless, and are designed to amplify local cell death in a way that subsequently recruits adaptive immunity. The combination with an anti-PD-L1 agent is not incidental — it is load-bearing to the hypothesis that local radiosensitization can prime systemic immune response.
The feasibility finding carries its own weight. Intratumoral injection in stage III inoperable lung cancer — involving both primary tumor and involved nodes — requires interventional pulmonology expertise and raises real procedural questions about access, safety, and reproducibility across sites. The data suggest it can be done safely, which clears a prerequisite for any larger randomized expansion. CONVERGE is structured in parts, with Part 1 functioning as a safety and preliminary efficacy run-in before broader randomization. The signal here will directly shape how aggressively Johnson & Johnson, which now holds global co-development rights under the 2023 Janssen agreement, pushes enrollment and endpoint selection in subsequent parts.
The pivotal question CONVERGE must eventually answer is whether the complete response signal translates into progression-free and overall survival benefit at scale — and whether the Phase 3 infrastructure being built around NBTXR3 in head and neck cancer through NANORAY-312 can be leveraged to accelerate the lung program. Watch the Part 2 randomization criteria: if J&J widens eligibility based on these Part 1 feasibility results, that is the clearest indicator this asset is being accelerated beyond a supporting role.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
